The company reaffirmed its underlying profit forecast but said full-year results were likely to depend heavily on first-half earnings. — Bloomberg
SYDNEY: Australia’s CSL Ltd reports a 10% jump in its first-half profit, surpassing analyst estimates, as an uptick in blood plasma collections and the acquisition of Swiss drugmaker Vifor Pharma AG boost its bottom line.
CSL, which earns most of its profit from selling blood plasma treatments for rare diseases, said plasma collections rose 10% above pre-pandemic levels and its immunoglobulin product sales increased 19%.
“The strong growth we have seen in plasma collections and our immunoglobulins franchise is expected to continue,” said chief executive officer Paul Perreault.
The company also reaffirmed its underlying profit forecast, which was upgraded in mid-October last year, but said full-year results were likely to depend heavily on first-half earnings.
The biotech giant said its underlying net profit after tax attributable for the six months ended Dec 31 was US$1.96bil (RM8.5bil) on a constant currency basis, higher than the US$1.78bil (RM7.8bil) last year. — Reuters
